Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 17, 2005. The report details a share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 17, 2004, and discloses changes in directors' interests related to the GlaxoSmithKline Employee Trust.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to the share buyback:
- Shares Purchased: 800,000 Ordinary shares.
- Purchase Price: 1,244.229 pence per share.
- Treasury Holdings: 72,733,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,866,498,002 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 800,000 shares on February 17, 2005. Additionally, the GlaxoSmithKline Employee Trust transferred 132,783 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991 on February 16, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 800,000 share repurchase based on the disclosed price of 1,244.229 pence.
- Confirm the updated total share capital and Treasury share count in subsequent filings.
- Review the impact of the 132,783 shares transferred from the GSK Trust on the Employee Share Option Plan.
- Note that this filing does not contain quarterly or annual financial performance data.